UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3388) 3388
Patent (1372) 1372
Conference Proceeding (40) 40
Newspaper Article (18) 18
Book Chapter (6) 6
Dissertation (4) 4
Magazine Article (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1195) 1195
life sciences & biomedicine (838) 838
chemistry (713) 713
humans (639) 639
electricity (620) 620
metallurgy (543) 543
male (515) 515
female (491) 491
middle aged (442) 442
basic electric elements (426) 426
physics (416) 416
aged (383) 383
adult (349) 349
electric solid state devices not otherwise provided for (315) 315
semiconductor devices (315) 315
oncology (289) 289
organic chemistry (283) 283
physical sciences (258) 258
human necessities (250) 250
heterocyclic compounds (236) 236
technology (234) 234
dyes (209) 209
adhesives (206) 206
miscellaneous applications of materials (205) 205
miscellaneous compositions (205) 205
natural resins (205) 205
paints (205) 205
polishes (205) 205
gastroenterology & hepatology (193) 193
performing operations (182) 182
transporting (182) 182
materials for miscellaneous applications, not provided forelsewhere (178) 178
materials science (168) 168
treatment outcome (164) 164
retrospective studies (160) 160
aged, 80 and over (149) 149
electric communication technique (141) 141
calculating (139) 139
computing (139) 139
counting (139) 139
analysis (134) 134
gastroenterology and hepatology (132) 132
hygiene (129) 129
medical or veterinary science (129) 129
materials science, multidisciplinary (126) 126
original (118) 118
original article (116) 116
agriculture (115) 115
animals (113) 113
prognosis (112) 112
animal husbandry (104) 104
fishing (104) 104
forestry (104) 104
hunting (104) 104
risk factors (104) 104
trapping (104) 104
surgery (98) 98
biocides, e.g. as disinfectants, as pesticides, as herbicides (97) 97
pest repellants or attractants (97) 97
plant growth regulators (97) 97
preservation of bodies of humans or animals or plants or partsthereof (97) 97
lung neoplasms - drug therapy (93) 93
science & technology - other topics (92) 92
preparations for medical, dental, or toilet purposes (87) 87
cancer (85) 85
carcinoma, non-small-cell lung - drug therapy (84) 84
acyclic or carbocyclic compounds (83) 83
chemotherapy (81) 81
physics, applied (77) 77
research (77) 77
diagnosis (76) 76
optics (76) 76
care and treatment (75) 75
chemistry, physical (75) 75
general tagging of cross-sectional technologies spanning over several sections of the ipc (74) 74
general tagging of new technological developments (74) 74
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (74) 74
nanoparticles (73) 73
prospective studies (72) 72
young adult (71) 71
general & internal medicine (70) 70
electric digital data processing (69) 69
follow-up studies (69) 69
medicine, general & internal (68) 68
mice (68) 68
disease-free survival (65) 65
mutation (65) 65
respiratory system (64) 64
nanostructure (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
electrochemistry (62) 62
lung neoplasms - genetics (62) 62
nanotechnology (62) 62
medical colleges (61) 61
electrodes (60) 60
lung cancer (60) 60
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (60) 60
chemistry, multidisciplinary (59) 59
compositions based thereon (58) 58
lung neoplasms - pathology (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3793) 3793
Korean (1635) 1635
French (219) 219
Chinese (138) 138
German (95) 95
Japanese (35) 35
Spanish (12) 12
Portuguese (11) 11
Danish (3) 3
Polish (3) 3
Hungarian (2) 2
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Cell survival | Medical treatment | FDA approval | Health care facilities | Survival | Patients | Evidence-based medicine | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Scientific reports, ISSN 2045-2322, 02/2019, Volume 9, Issue 1, pp. 2798 - 2798
... bicarbonate level at admission in hospitalised patients Sung Yoon Lim1, Youngmi park2, Ho Jun Chin1,3, Ki Young Na1,3, Dong-Wan Chae1,3 and sejoong Kim 1,3 Although low... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Bicarbonate | Kidneys | Mortality | Long-term effects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article